Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world

HIGHLIGHTS

• who: Min Fang et al. from the Xiangya, Central South University, China have published the research work: Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable nonu2013small cell lung cancer in real world, in the Journal: (JOURNAL)
• what: The authors retrospectively collected data from 211 patients with resectable stage IB-IIIB NSCLC, who have received neoadjuvant immunotherapy plus chemotherapy and underwent complete tumor resection in the center to evaluate the efficacy and safety.
• how: The results showed that 41 patients had underwent tumor resection 34 (83%) had achieved MPR 26 (63 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.